FDA Grants Priority Review to Palvella Therapeutics' Qtorin Rapamycin Application
Palvella Therapeutics (PVLA) shares rose following news that the U.S. Food and Drug Administration (FDA) has granted priority review for its New Drug Application (NDA). The application is for Qtorin rapamycin, a topical mTOR inhibitor intended for medical use. Priority review is an expedited process designed to accelerate the availability of drugs that offer significant improvements in the safety or effectiveness of the treatment, place, or condition for which it is intended. This regulatory milestone provides a clearer timeline for potential commercialization of Palvella's lead asset.
Tickers: $PVLA